About: Yusuke Kawamura

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Yusuke Kawamura Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0001-6148-0042)

Attributes	Values
rdf:type	Item
description	forskare (sv) 연구원 (ko) araştırmacı (tr) wetenschapper (nl) дослідник (uk) изилдөөчү (ky) 研究者 (zh) investigador xaponés (ast) researcher (ORCID 0000-0001-6148-0042) (en)
rdfs:label	Yusuke Kawamura (en) Yusuke Kawamura (nl) Yusuke Kawamura (ast) Yūsuke Kawamura (tr) 川村祐介 (ja)
skos:prefLabel	Yusuke Kawamura (en) Yusuke Kawamura (nl) Yusuke Kawamura (ast) Yūsuke Kawamura (tr) 川村祐介 (ja)
name	Yusuke Kawamura (en) Yusuke Kawamura (nl) Yusuke Kawamura (ast) Yūsuke Kawamura (tr) 川村祐介 (ja)
instance of	wds:Q90407021-28BDD7FF-49BB-498F-BA5F-BECBD16C5025
instance of	Homo sapiens
occupation	wds:Q90407021-C0118CEE-84B2-4E5C-BB69-0D9ACB2D5EAE
employer	wds:Q90407021-a71c46b5-456e-69fd-5c25-c44b41809b28
sex or gender	wds:Q90407021-36790b49-4aaa-d166-8b76-99f36b8821c4
country of citizenship	wds:Q90407021-3cc16fcf-4f29-1834-ce6a-70eb0aff6264
educated at	wds:Q90407021-4A8CD88D-3E07-4B63-ABC4-124920787B9C
occupation	researcher
employer	Toranomon Hospital
sex or gender	male
country of citizenship	Japan
educated at	Toranomon Hospital
ORCID iD	wds:Q90407021-EAF5E2BF-CED6-42F1-8DB5-AAD62CEEC211
ORCID iD	https://orcid.org/0000-0001-6148-0042
ORCID iD	0000-0001-6148-0042
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q90407021
is author of	Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Necessities of interferon therapy in elderly patients with chronic hepatitis C. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software